Fresenius Medical Care

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

VR Medical, established in 2009, is a US-based company that specializes in providing comprehensive manufacturing solutions for medical device companies and distributors. The company focuses on offering a single-sourced solution for new product development, outsourcing, contract manufacturing, and secure product distribution within China. VR Medical's unique capabilities include the development and low-cost manufacturing of disposable products and electronic devices, catering to private labels, OEMs, and distributors globally. Their medical devices are designed to support various medical markets, including respiratory care, critical care, blood purification, and advanced wound care.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

SafeRide Health is a healthcare technology company specializing in non-emergency medical transportation. Its platform leverages AI and data analytics to enhance patient experience, improve population health, and optimize fleet management for healthcare providers.

Humacyte specializes in developing human tissue-based products for regenerative medicine and vascular surgery. It creates acellular extracellular matrices using banked vascular smooth muscle cells, which are then decellularized to eliminate rejection risks. These matrices serve as off-the-shelf tissue-engineered grafts for patients requiring vascular repair or replacement.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

BioIntelliSense is a health technology company that provides continuous remote health monitoring through a medical-grade wearable data platform. Its Data-as-a-Service offering collects multi-parameter vital signs, physiological biometrics, and symptomatic events via devices such as BioButton and BioSticker, enabling remote monitoring, early detection, and clinical insights. The FDA-cleared BioButton and BioSticker devices facilitate monitoring and data-driven care. The platform delivers high-resolution patient trending and reporting to support decision-making across care settings, from hospital to home. The devices monitor metrics including skin temperature, resting heart rate, resting respiratory rate, gait, body position, activity, falls, sleep, and symptom patterns such as coughing and sneezing. The solution aims to improve patient outcomes, streamline clinical workflows, and reduce hospital readmissions through continuous screening and predictive analytics.

SafeRide Health is a healthcare technology company specializing in non-emergency medical transportation. Its platform leverages AI and data analytics to enhance patient experience, improve population health, and optimize fleet management for healthcare providers.

Modulim is a company developing light-based imaging devices based on spatial frequency domain imaging (SFDI) for tissue and vascular assessment. The Clarifi Imaging System helps identify patients at risk of complications such as diabetic foot ulcers and potential limb loss due to compromised circulation, enabling clinicians to intervene earlier and protect limbs. The company's devices support skin assessment and treatment monitoring, providing tools to prevent, diagnose, and monitor medical skin conditions.

Tridiuum, Inc. is a digital health company that specializes in providing software solutions for behavioral health providers, patients, and health systems. Founded in 1997 and based in Philadelphia, the company operates a cloud-based platform known as Tridiuum1, which focuses on behavioral health outcomes management. This platform enables the monitoring of patients' symptoms and treatment progress, thereby enhancing patient experiences and outcomes in healthcare settings. Tridiuum's technology integrates digital health assessments with analytics to identify behavioral health issues, assign risk scores, and deliver real-time alerts at the point of care. Additionally, it supports features like video-based virtual visits, equipping clinicians to effectively evaluate, predict, and manage the care of patients facing various conditions. The company is driven by a team of experts in behavioral medicine and digital health technologies, with a strong clinical foundation rooted in research and evidence-based practices.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, specializing in innovative solutions for patients with congestive heart failure. Founded in 2011, the company has developed the V-LAP, the first in-heart microcomputer designed to enhance treatment for heart failure patients by facilitating daily monitoring of left atrial pressure (LAP). This miniature wireless implant is a groundbreaking device that operates without batteries and can transmit data from deep within the body, offering a reliable means of detecting potential deterioration in heart failure. The V-LAP has been recognized as an effective predictor of heart failure worsening, thereby improving patients' quality of life and life expectancy. Vectorious is currently conducting clinical studies in various European countries, including Italy, Germany, and the UK, to obtain regulatory approval, with plans to initiate a clinical study in the United States.

Humacyte specializes in developing human tissue-based products for regenerative medicine and vascular surgery. It creates acellular extracellular matrices using banked vascular smooth muscle cells, which are then decellularized to eliminate rejection risks. These matrices serve as off-the-shelf tissue-engineered grafts for patients requiring vascular repair or replacement.

Vectorious Medical Technologies Ltd. is a medical device company based in Tel Aviv, Israel, specializing in innovative solutions for patients with congestive heart failure. Founded in 2011, the company has developed the V-LAP, the first in-heart microcomputer designed to enhance treatment for heart failure patients by facilitating daily monitoring of left atrial pressure (LAP). This miniature wireless implant is a groundbreaking device that operates without batteries and can transmit data from deep within the body, offering a reliable means of detecting potential deterioration in heart failure. The V-LAP has been recognized as an effective predictor of heart failure worsening, thereby improving patients' quality of life and life expectancy. Vectorious is currently conducting clinical studies in various European countries, including Italy, Germany, and the UK, to obtain regulatory approval, with plans to initiate a clinical study in the United States.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in developing precision therapies for cardiovascular and renal diseases. Founded in 2014, the company focuses on researching and commercializing innovative treatments aimed at addressing chronic kidney disease, particularly in patients with atherosclerotic cardiovascular disease and inflammation, as well as conditions like high triglyceride-induced acute pancreatitis. Corvidia Therapeutics is recognized for its approach that targets specific biologic pathways, enabling healthcare providers to deliver more effective therapies to patients with unique sensitivities. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S.

Modulim is a company developing light-based imaging devices based on spatial frequency domain imaging (SFDI) for tissue and vascular assessment. The Clarifi Imaging System helps identify patients at risk of complications such as diabetic foot ulcers and potential limb loss due to compromised circulation, enabling clinicians to intervene earlier and protect limbs. The company's devices support skin assessment and treatment monitoring, providing tools to prevent, diagnose, and monitor medical skin conditions.

NxStage Medical, Inc. is a medical technology company focused on developing, manufacturing, and marketing products for the treatment of end-stage renal disease and acute kidney failure. The company's primary product, the NxStage System One, is a portable hemodialysis system designed for home use, allowing patients to manage their treatment more conveniently. In addition to the System One, NxStage offers the PureFlow SL, which integrates water purification and dialysate production for home or in-center use, as well as chronic cartridges that support more flexible renal replacement therapy schedules. The company also provides a range of disposable products for in-center dialysis treatments, including blood tubing sets and needles. NxStage Medical operates dialysis centers and delivers training services, along with a telehealth platform called Nx2me Connected Health, which facilitates remote monitoring and management of home hemodialysis treatments. Founded in 1998 and based in Lawrence, Massachusetts, NxStage Medical operates as a subsidiary of Fresenius Medical Care Holdings, Inc.

Cura Group is a prominent provider of day hospital facilities in Australia, established in 2008. The company operates private hospital facilities that focus on day procedures, specializing in various medical fields such as ophthalmology, plastic, reconstructive and cosmetic surgery, orthopedic surgery, oral surgery, and pediatric services. By concentrating on these areas, Cura Group aims to enhance patient health and streamline the surgical process, providing quality care in a more efficient setting.

XENiOS AG specializes in developing medical devices aimed at treating acute and chronic lung failure, as well as cardiac insufficiency. The company offers a comprehensive range of products, including the iLA active platform for extrapulmonary lung support, iLA Membrane Ventilator for pumpless lung support, and various cannulas and pumps designed for cardiac surgery applications. Additionally, XENiOS provides innovative solutions such as the NovaTherm Heater/Cooler for blood temperature management and the deltastream series for monitoring and managing patient parameters during treatment. The company is uniquely positioned in the market by offering minimally invasive, disposable therapies that address both lung and heart conditions on a single platform, which is not available from other manufacturers. Founded in 2013 and based in Heilbronn, Germany, XENiOS AG also delivers clinical application support, training, and customer service to healthcare providers. As of late 2016, it operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.

Sparsh Nephrocare operates in-hospital dialysis units across India and South East Asia, aiming to make dialysis treatment accessible to kidney failure patients. The company pioneered the concept of "in-hospital" dialysis centers and has partnered with premier government institutes under Public Private Partnership models. Sparsh Nephrocare provides advanced machines, well-trained technicians, electronic medical record-keeping adhering to NABH norms, and manages complete operations, relieving hospitals of operational burdens. Its mission is to democratize renal care by creating an efficient ecosystem for dialysis treatment.

National Cardiovascular Partners is an operator of outpatient endovascular, vascular, and cardiovascular services, focusing on providing care in a convenient setting. Partnering with over 200 physicians, the company manages 21 outpatient vascular centers across six states. Its facilities include independent cardiac catheterization and vascular labs, where physician entrepreneurs serve as majority stakeholders, retaining both clinical and financial control. National Cardiovascular Partners oversees the administrative aspects of these centers, allowing physician partners to concentrate on delivering high-quality and innovative patient care.

Sound Physicians is a healthcare company focused on enhancing the quality of inpatient care through its network of over 1,000 hospitalist and post-acute physicians. The company partners with more than 70 hospitals and an increasing number of post-acute care centers across the United States. It provides a range of services that span the acute episode of care, including emergency medicine, critical care, hospital medicine, population health, telemedicine, and physician advisory services. By offering these comprehensive solutions, Sound Physicians aims to improve patient satisfaction and financial performance for its hospital partners, ultimately driving better outcomes in healthcare delivery.

MedSpring is a walk in clinic when someone needs a immediate medical care.

Astrana Health is a physician-driven integrated population health management company focused on delivering coordinated care to Medicare, Medicaid, and Commercial patients under risk-based contracts with payors. The company improves patient quality of life and reduces healthcare costs by providing comprehensive services through contracted physicians and ancillary support services.

Liberty Dialysis, LLC, based in Mercer Island, Washington, develops, owns, and operates dialysis clinics across the United States. Founded in 2002, the company is dedicated to providing quality care for patients with chronic kidney disease through a comprehensive approach that includes outreach programs and home dialysis options. Liberty Dialysis emphasizes patient education, aiming to inform patients, their families, and the community about kidney health. The company operates clinics in multiple states, including Alaska, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Indiana, Maryland, Michigan, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Texas, Utah, Virginia, West Virginia, and Wisconsin. As of 2012, Liberty Dialysis operates as a subsidiary of Fresenius Medical Care AG & Co. KGaA.

American Access Care is a hospital & health care company that provides dialysis access management services.

Renal Advantage Inc. is a Brentwood, Tennessee-based provider of outpatient dialysis services, focusing on patients with chronic kidney ailments. The company operates over 154 freestanding renal dialysis centers across the United States. Founded by experienced healthcare executives, Renal Advantage emphasizes a Center-Centric operating philosophy, which aims to enhance the experiences of both patients and healthcare professionals. By prioritizing high-quality care, Renal Advantage seeks to improve the quality of life for its patients while fostering positive relationships with partners and staff.

Hema Metrics is a medical monitoring devices company. Hema Metrics serves thousands of patients worldwide and provides products for more than 1 million treatments each year.

Xcorporeal is a medical device company focused on creating innovative extra-corporeal platform technologies designed to replace the functions of failing or failed human organs. The company's products aim to provide critical solutions in organ replacement, enhancing patient care and outcomes in various medical conditions. Through its advanced technology, Xcorporeal seeks to address the growing need for effective organ replacement options in the healthcare industry.

Renal Solutions is a company based in Warrendale, Pennsylvania, that specializes in the development of dialysis products and services. Founded in 2000, the company focuses on creating integrated medical devices for sorbent hemodialysis treatment, which is designed to improve care for patients suffering from chronic and acute kidney failure. By offering a clinical care model, Renal Solutions enables healthcare practitioners to provide convenient and flexible treatment options that utilize sorbent-based dialysis technology. In November 2007, Renal Solutions was acquired by Fresenius Medical Care, enhancing its capacity to deliver innovative renal care solutions.

Jiate Excelsior Co., Ltd. provides dialysis services for treating hemodialysis patients.

Renal Care Group, Inc. provides dialysis services to patients with chronic kidney failure, also known as end-stage renal disease (ESRD). It provides its services for the treatment of chronic and acute renal diseases. The company also provides ancillary service, which is the administration of erythropoietin, also known as Epogen, a bioengineered protein that stimulates the production of red blood cells. As of December 31, 2005, Renal Care Group operated 456 outpatient dialysis centers in 34 states with 7,894 certified dialysis stations and provided inpatient dialysis services to approximately 200 acute care hospitals. The company was founded in 1996 and is headquartered in Nashville, Tennessee. As of March 31, 2006, Renal Care Group, Inc. is a subsidiary of Fresenius Medical Care AG & Co. KGAA.